// App-Quantinova.ai

BSH2020‐PO‐147 : Assessment of longer‐term efficacy, safety, and haematological improvement in the phase 3, randomised, double‐blind, placebo‐controlled MEDALIST trial of luspatercept to treat anaemia in patients with lower‐risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions

Researchers

Presenter

  • G. J. Mufti

Principal Investigators

  • P. Vyas

  • R. Buckstein

  • V. Santini

  • M. Dez-Campelo

  • C. Finelli

  • O. Ilhan

  • M. A. Sekeres

  • R. S. Komrokji

  • A. M. Zeidan

  • A. Verma

  • A. Laadem

  • P. G. Linde

  • A. F. List

  • U. Platzbecker

  • G. Garcia-Manero

  • P. Fenaux

Medical Centers

  • Department of Haemato‐Oncology, King's College London, London

  • Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • MDS Unit, Azienda Ospedaliero Universitaria

  • CRIMM, AOU Careggi, University of Florence, Florence, Italy

  • Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca,Salamanca,Espagne

  • Department of Oncology and Hematology, S. Orsola‐Malpighi University Hospital, Bologna, Italy

  • Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey

  • Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

  • Moffitt Cancer Center, Tampa, FL

  • Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT

  • Department of Medicine (Oncology), Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY

  • Bristol-Myers Squibb, Summit, NJ

  • Acceleron Pharma, Cambridge, MA

  • Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

  • Service d'Hematologie Seniors/Hopital Saint-Louis, Universite Paris 7, Paris, France

Locations

  • United Kingdom

  • Canada

  • Italy

  • Spain

  • Turkey

  • United States

  • Germany

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

  • Thrombocytopenia

  • Neutropenia

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Red Blood Cells

Drug/Treatment

  • luspatercept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Controlled

Phase

  • III

Study Id's

  • NCT02631070

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved